Core Viewpoint - The company Jingtai Holdings (2228.HK) has seen a significant stock price increase, attributed to the successful milestone achievement of its incubated company ReviR's innovative drug pipeline RTX-117, which has received dual approval in China and the U.S. [1] Group 1: Stock Performance - Jingtai Holdings' stock price rose by 6.17% to HKD 14.28, reaching a new high since October 10, 2025 [1] - Year-to-date, the stock has increased by 50.95%, significantly outperforming the Hang Seng Index, which rose over 5% in the same period [1] Group 2: Milestone Achievement - ReviR's RTX-117 has achieved a significant milestone with the approval of its Investigational New Drug (IND) application in both China and the U.S. [1] - As a result of this milestone, Jingtai Holdings will receive milestone payments totaling tens of millions of Hong Kong dollars from ReviR [1] Group 3: Drug Pipeline and Market Potential - RTX-117 is the first milestone achievement in a series of research pipelines developed through deep collaboration between Jingtai and ReviR, with clinical data and approval speed exceeding expectations [1] - The drug has the potential to expand its indications significantly, with an estimated coverage of over 50 million people, nearly 20 times the current number of CMT patients [1]
港股异动丨晶泰控股涨超6%创逾3个月新高 年内累涨超50% 孵化企业新药RTX-117获中美临床批件
Ge Long Hui·2026-01-14 08:00